Compare Procter & Gamble Co (PG) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Procter & Gamble Co vs Zimmer Biomet Holdings Inc — how do they compare? Procter & Gamble Co trades at $149.52 (market cap $344.87B), while Zimmer Biomet Holdings Inc trades at $88.69 (market cap $17.20B). The key difference: Procter & Gamble Co is far larger — about 20.1× Zimmer Biomet Holdings Inc's market cap, and Procter & Gamble Co pays the higher dividend (2.94%). Which is the better fit depends on your goals.
| PG | ZBH | |
|---|---|---|
Market Cap | $344.87B | $17.20B |
Volume | 6,423,436 | — |
Sector | Consumer Staples | Health |
52-Week High | $167.18 | $107.71 |
52-Week Low | $138.10 | $79.58 |
Enterprise Value | $370.34B | $24.25B |
Dividend Yield | 2.94% | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Procter & Gamble (PG) trades at $149.15, showing minimal daily movement. The stock exhibits neutral technical signals with support near $147 and resistance at $150. Fundamentally, PG maintains stable revenue near $84.3 billion and strong net income margins above 19%, supported by consistent earnings beats. Recent news highlights its dividend reliability amid market volatility, with a 69-year track record of increases. Analyst consensus is bullish with a $160.50 price target, though valuation multiples trade at premiums to peers.
PG offers steady growth with dividend safety but faces near-term headwinds from premium valuations and modest revenue expansion. Upside depends on execution of supply chain efficiencies and sustained consumer demand. Risks include competitive pressures and economic sensitivity. Institutional ownership trends show mixed positioning, reflecting cautious optimism.
Zimmer Biomet (ZBH) trades at $88.92, down 2.41% on the day, with a bearish technical signal but strong fundamentals including a 70.03% gross margin and three consecutive quarterly EPS beats. Revenue grew to $8.23B in 2025, though net income margin compressed to 8.56%. The company announced a $1 billion share repurchase increase and expansion in India, while maintaining a dividend.
The stock offers a 10% upside to the $97.67 consensus price target, supported by value metrics and operational strength, but faces risks from rising debt levels and competitive pressures. Analyst sentiment is mixed with 40% buy ratings, suggesting cautious optimism amid near-term technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Procter & Gamble Co
The Procter & Gamble Company manufactures and markets consumer products in countries throughout the world. The Company provides products in the laundry and cleaning, paper, beauty care, food and beverage, and health care segments. Procter & Gamble products are sold primarily through mass merchandisers, grocery stores, membership club stores, drug stores, and neighborhood stores.
Read more on PG →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
